Isarna Therapeutics raises 13m from AT NewTec, MIG


euro8_170sqGerman pharmaceutical startup Isarna Therapeutics has raised a €13m from new private equity investor AT NewTec and existing backer MIG Verwaltungs.

The company will use the proceeds to advance its pipeline of TGF-β inhibitors that stimulate the human immune system to effectively fight cancer.

MIG Verwaltungs managing director Matthias Kromayer said, “MIG is convinced that an immunotherapy approach to treating cancer has the potential to change the paradigm of current standard of care.

“We have great confidence in both Isarna’s pioneering approach to leveraging TGF-β and the company’s management.”

Recent venture capital deals in Germany include Star Ventures Funds’s sale of 20 assets to secondary direct investor Saints Capital.

Copyright © 2014 AltAssets